Loading data for ANAB — first visit, this takes a few seconds.

アラート

AnaptysBio Inc. (ANAB)

NasdaqGS: ANAB · リアルタイム株価 · USD

58.99

-0.70 (-1.17%)

終値時点： Aug 18, 2026, 3:59 PM

59.00

+0.02%

寄り付き前: 4:02 AM

-1.17% (1D)

買気配	42.7
時価総額	1.75B
売上高（TTM）	232.39M
純利益（TTM）	-26.79M
ベータ	0.40
EPS（TTM）	-1.02
PER（TTM）	n/a
予想PER	11.27
PBR（TTM）	134.37
PSR（TTM）	7.52
Earnings Date	Aug 18, 2026

売気配	75.02
出来高	256,912
平均出来高（20日）	611,900
始値	58.90
前日終値	59.69
当日レンジ	58.16 - 59.99
52週レンジ	11.40 - 72.36
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ANABについて

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; A...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Jan 26, 2017

従業員数 104

上場取引所 NasdaqGS

ティッカー ANAB

ウェブサイト https://www.anaptysbio.com

企業情報の全文

業績

2025年のAnaptysBioの売上高は234.6Mで、前年の91.28Mから157.01%の増加でした。利益は-13.23Mで、-90.89%の減少でした。

財務諸表

決算サプライズ

AnaptysBioはMar 3, 2026に四半期決算を発表しました：

売上高は $25.56M で、予想を下回りました $0, うち -7.98% の前年比減少.

EPSは 1.58 で、予想を上回りました 0.65, うち 319.44% の前年比増加にあたります.

次回決算発表

AnaptysBio Inc.の決算発表予定日は Aug 18, 2026, 引け後の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1日前 · Insider Monkey

GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net retur...

5日前 · Zacks

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1か月前 · Insider Monkey

What Makes AnaptysBio (ANAB) an Investment Bet?

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for t...

2か月前 · Zacks

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

3か月前 · Zacks

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...

2ページ中1ページ

AnaptysBio Inc. (ANAB)